ANX007 for Age-Related Macular Degeneration
(ARCHER II Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The primary purpose of the study is to determine if IVT injections of ANX007 every month reduce vision loss in participants with GA secondary to age-related macular degeneration (AMD).
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. Please consult with the trial coordinators for more details.
Who Is on the Research Team?
Clinical Trials
Principal Investigator
Annexon, Inc.
Are You a Good Fit for This Trial?
This trial is for individuals with Geographic Atrophy (GA), a form of age-related macular degeneration that leads to vision loss. Participants should not have other eye conditions that could interfere with the study or be taking treatments that affect the immune system.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive ANX007 or Sham IVT injections every month
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- ANX007
Find a Clinic Near You
Who Is Running the Clinical Trial?
Annexon, Inc.
Lead Sponsor